Through the window of oncology R&D

With the sad and very gloomy news that Incyte’s IDO inhibitor, epacadostat, has missed in the phase 3 ECHO–301 study in metastatic melanoma, is there still hope for IO-IO combinations in the pipeline?

Here, we take a quick look at the Incyte announcement briefly, but more importantly, we also look forward to other combinations that might be of interest to those following the cancer immunotherapy space.

Not surprisingly, there is a lot to look out for as our sixth post in the AACR18 Preview series highlights as we look through the IO window to potential future developments of interest.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

Posted by